{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:22:46Z","timestamp":1783650166728,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000098","name":"National Institutes of Health Clinical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glioblastoma is the most common primary brain malignancy and carries with it a poor prognosis. New agents are urgently needed, however nearly all Phase III trials of GBM patients of the past 25\u00a0years have failed to demonstrate improvement in outcomes. In 2019, the National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) Glioblastoma Working Group (GBM WG) identified 5 broad areas of research thought to be important in the development of new herapeutics for GBM. Among those was optimizing radioresponse for GBM in situ<jats:italic>.<\/jats:italic> One such strategy to increase radiation efficacy is the addition of a radiosensitizer to improve the therapeutic ratio by enhancing tumor sensitivity while ideally having minimal to no effect on normal tissue. Historically the majority of trials using radiosensitizers have been unsuccessful, but they provide important guidance in what is required to develop agents more efficiently. Improved target selection is essential for a drug to provide maximal benefit, and once that target is identified it must be validated through pre-clinical studies. Careful selection of appropriate in vitro and in vivo models to demonstrate increased radiosensitivity and suitable bioavailability are then necessary to prove that a drug warrants advancement to clinical investigation. Once investigational agents are validated pre-clinically, patient trials require consistency both in terms of planning study design as well as reporting efficacy and toxicity in order to assess the potential benefit of the drug. Through this paper we hope to outline strategies for developing effective radiosensitizers against GBM using as models the examples of XPO1 inhibitors and HDAC inhibitors developed from our own lab.<\/jats:p>","DOI":"10.1186\/s13014-021-01918-y","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T18:04:18Z","timestamp":1632852258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma"],"prefix":"10.1186","volume":"16","author":[{"given":"Charlotte","family":"Degorre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Tofilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Camphausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1077-120X","authenticated-orcid":false,"given":"Peter","family":"Mathen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"issue":"10","key":"1918_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"key":"1918_CR2","unstructured":"National Cancer Institute Clinical Trials and Translational Research Advisory Committee Glioblastoma Working Group Report July 17, 2019. National Cancer Institute Clinical Trials and Translational Research Advisory Committee Glioblastoma Working Group. 2019. https:\/\/deainfo.nci.nih.gov\/advisory\/ctac\/0719\/Att_12_GBM%20WG%20Final%20Report%20CTAC%207-17-19_v1.pdf . Accessed 21 April 2021."},{"issue":"5","key":"1918_CR3","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0360-3016(97)00911-5","volume":"40","author":"K Nakagawa","year":"1998","unstructured":"Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1998;40(5):1141\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1918_CR4","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO.2002.20.6.1635","volume":"20","author":"JL Chan","year":"2002","unstructured":"Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol. 2002;20(6):1635\u201342.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1918_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3109\/07357909209024816","volume":"10","author":"MA Shenoy","year":"1992","unstructured":"Shenoy MA, Singh BB. Chemical radiosensitizers in cancer therapy. Cancer Invest. 1992;10(6):533\u201351.","journal-title":"Cancer Invest"},{"issue":"1","key":"1918_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tips.2017.11.003","volume":"39","author":"H Wang","year":"2018","unstructured":"Wang H, Mu X, He H, Zhang XD. Cancer radiosensitizers. Trends Pharmacol Sci. 2018;39(1):24\u201348.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"1918_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.clon.2007.03.010","volume":"19","author":"P Wardman","year":"2007","unstructured":"Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol). 2007;19(6):397\u2013417.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"1918_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/neuonc\/nox144","volume":"20","author":"JJ Mandel","year":"2018","unstructured":"Mandel JJ, Yust-Katz S, Patel AJ, et al. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 2018;20(1):113\u201322.","journal-title":"Neuro Oncol"},{"issue":"10","key":"1918_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/14737140.2018.1496824","volume":"18","author":"JJ Mandel","year":"2018","unstructured":"Mandel JJ, Youssef M, Ludmir E, Yust-Katz S, Patel AJ, De Groot JF. Highlighting the need for reliable clinical trials in glioblastoma. Expert Rev Anticancer Ther. 2018;18(10):1031\u201340.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"1918_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.semradonc.2016.06.003","volume":"26","author":"CD Corso","year":"2016","unstructured":"Corso CD, Bindra RS. Success and failures of combined modalities in glioblastoma multiforme: old problems and new directions. Semin Radiat Oncol. 2016;26(4):281\u201398.","journal-title":"Semin Radiat Oncol"},{"issue":"7216","key":"1918_CR11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"Cancer Genome Atlas Research N","year":"2008","unstructured":"Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061\u20138.","journal-title":"Nature"},{"issue":"14","key":"1918_CR12","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1016\/j.ejca.2013.05.013","volume":"49","author":"AT Tandle","year":"2013","unstructured":"Tandle AT, Kramp T, Kil WJ, et al. Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation. Eur J Cancer. 2013;49(14):3020\u20138.","journal-title":"Eur J Cancer"},{"key":"1918_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.canlet.2019.07.018","volume":"462","author":"B Aguila","year":"2019","unstructured":"Aguila B, Morris AB, Spina R, et al. The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme. Cancer Lett. 2019;462:33\u201342.","journal-title":"Cancer Lett"},{"issue":"1","key":"1918_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13059-020-01995-4","volume":"21","author":"SJ Liu","year":"2020","unstructured":"Liu SJ, Malatesta M, Lien BV, et al. CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma. Genome Biol. 2020;21(1):83.","journal-title":"Genome Biol"},{"issue":"22","key":"1918_CR15","doi-asserted-by":"publisher","first-page":"12324","DOI":"10.1073\/pnas.1921531117","volume":"117","author":"Y Rajesh","year":"2020","unstructured":"Rajesh Y, Biswas A, Kumar U, et al. Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma. Proc Natl Acad Sci USA. 2020;117(22):12324\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1918_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccr.2006.03.030","volume":"9","author":"J Lee","year":"2006","unstructured":"Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5):391\u2013403.","journal-title":"Cancer Cell"},{"issue":"2","key":"1918_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1593\/neo.111794","volume":"14","author":"M Jamal","year":"2012","unstructured":"Jamal M, Rath BH, Tsang PS, Camphausen K, Tofilon PJ. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia. 2012;14(2):150\u20138.","journal-title":"Neoplasia"},{"key":"1918_CR18","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3389\/fonc.2019.01259","volume":"9","author":"YS Seo","year":"2019","unstructured":"Seo YS, Ko IO, Park H, et al. Radiation-induced changes in tumor vessels and microenvironment contribute to therapeutic resistance in glioblastoma. Front Oncol. 2019;9:1259.","journal-title":"Front Oncol"},{"issue":"9","key":"1918_CR19","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.dnarep.2008.05.005","volume":"7","author":"CA Banuelos","year":"2008","unstructured":"Banuelos CA, Banath JP, MacPhail SH, et al. Mouse but not human embryonic stem cells are deficient in rejoining of ionizing radiation-induced DNA double-strand breaks. DNA Repair (Amst). 2008;7(9):1471\u201383.","journal-title":"DNA Repair (Amst)"},{"issue":"10","key":"1918_CR20","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1158\/0008-5472.CAN-15-3050","volume":"76","author":"A Wahba","year":"2016","unstructured":"Wahba A, Rath BH, Bisht K, Camphausen K, Tofilon PJ. Polysome profiling links translational control to the radioresponse of glioblastoma stem-like cells. Cancer Res. 2016;76(10):3078\u201387.","journal-title":"Cancer Res"},{"issue":"8","key":"1918_CR21","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1158\/1535-7163.MCT-17-1303","volume":"17","author":"A Wahba","year":"2018","unstructured":"Wahba A, Rath BH, O\u2019Neill JW, Camphausen K, Tofilon PJ. The XPO1 inhibitor selinexor inhibits translation and enhances the radiosensitivity of glioblastoma cells grown in vitro and in vivo. Mol Cancer Ther. 2018;17(8):1717\u201326.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"1918_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.tcb.2007.02.003","volume":"17","author":"S Hutten","year":"2007","unstructured":"Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol. 2007;17(4):193\u2013201.","journal-title":"Trends Cell Biol"},{"issue":"1","key":"1918_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/genes6010124","volume":"6","author":"M Okamura","year":"2015","unstructured":"Okamura M, Inose H, Masuda S. RNA export through the NPC in eukaryotes. Genes (Basel). 2015;6(1):124\u201349.","journal-title":"Genes (Basel)"},{"issue":"7","key":"1918_CR24","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-15-0978","volume":"22","author":"I Ferreiro-Neira","year":"2016","unstructured":"Ferreiro-Neira I, Torres NE, Liesenfeld LF, et al. XPO1 inhibition enhances radiation response in preclinical models of rectal cancer. Clin Cancer Res. 2016;22(7):1663\u201373.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1918_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/neuonc\/not139","volume":"16","author":"J Kahn","year":"2014","unstructured":"Kahn J, Hayman TJ, Jamal M, et al. The mTORC1\/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro Oncol. 2014;16(1):29\u201337.","journal-title":"Neuro Oncol"},{"issue":"9","key":"1918_CR26","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1158\/0008-5472.CAN-12-0329","volume":"72","author":"TJ Hayman","year":"2012","unstructured":"Hayman TJ, Williams ES, Jamal M, Shankavaram UT, Camphausen K, Tofilon PJ. Translation initiation factor eIF4E is a target for tumor cell radiosensitization. Cancer Res. 2012;72(9):2362\u201372.","journal-title":"Cancer Res"},{"issue":"3","key":"1918_CR27","first-page":"268","volume":"7","author":"P Mathen","year":"2020","unstructured":"Mathen P, Rowe L, Mackey M, Smart D, Tofilon P, Camphausen K. Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma. Neurooncol Pract. 2020;7(3):268\u201376.","journal-title":"Neurooncol Pract"},{"issue":"5","key":"1918_CR28","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","volume":"92","author":"AV Krauze","year":"2015","unstructured":"Krauze AV, Myrehaug SD, Chang MG, et al. A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2015;92(5):986\u201392.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1918_CR29","first-page":"246","volume":"5","author":"AV Krauze","year":"2018","unstructured":"Krauze AV, Mackey M, Rowe L, et al. Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma. Neurooncol Pract. 2018;5(4):246\u201350.","journal-title":"Neurooncol Pract"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01918-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-021-01918-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01918-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T18:14:38Z","timestamp":1632852878000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-021-01918-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1918"],"URL":"https:\/\/doi.org\/10.1186\/s13014-021-01918-y","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}